Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845914 | 0.88 | FFAR1 (0.44) | FFAR1AOC3MCHR1ADRA1DADRA1A | |
| SCHEMBL16855792 | 0.88 | FFAR1 (0.44) | FFAR1AOC3MCHR1ADRA1DADRA1A | |
| SCHEMBL16845947 | 0.86 | FFAR1 (0.39) | FFAR1MCHR1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL23952791 | 0.86 | AOC3 (0.34) | AOC3MCHR1ADRA1DADRA1AADRA1B | |
| SCHEMBL18959461 | 0.77 | KDM4E (0.34) | FFAR1MCHR1ADRA1DADRA1AADRA1B | |
| SCHEMBL18940301 | 0.76 | FFAR1 (0.40) | FFAR1AOC3 | |
| SCHEMBL23952798 | 0.73 | ALDH1A1 (0.35) | FFAR1AOC3ADRA1DADRA1AADRA1B | |
| SCHEMBL16845945 | 0.73 | FFAR1 (0.51) | FFAR1 | |
| SCHEMBL18940300 | 0.73 | FFAR1 (0.51) | FFAR1 | |
| SCHEMBL23952856 | 0.72 | FFAR1 (0.36) | FFAR1AOC3MCHR1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| WO-2015095256-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015089809-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | FFAR1 13/4885AOC3 4488/4885MCHR1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.